Still hope for schistosomiasis vaccine

Ricciardi, Alessandra; Ndao, Momar

doi:10.1080/21645515.2015.1059981

Cited by 21 publications

(23 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Without those additional interventions, re-infection rates will likely remain very high [18, 19]. However, a vaccine against Schistosoma could potentially overcome the challenges posed by mass treatment [17]; but currently none is commercially available [20]. Various antigens and vaccine candidates have been proposed [21] and some are investigated in clinical trials [22, 23] but none is yet readily approved and used for the public.…”

Section: Introductionmentioning

confidence: 99%

Perceptions about interventions to control schistosomiasis among the Lake Victoria island communities of Koome, Uganda

et al. 2017

View full text Add to dashboard Cite

BackgroundPraziquantel-based mass treatment is the main approach to controlling schistosomiasis mansoni in endemic areas. Interventions such as provision and use of safe water, minimising contact with infested water, disposal of stool in latrines and snail control provide key avenues to break the transmission cycle and can sustain the benefits of mass treatment in the long term. Efforts are also being made to develop a schistosomiasis vaccine which, if effective, might reduce the incidence of re-infection after treatment. However, any interventions deployed need to be acceptable to, and sustainable by, the target communities.MethodsIn this qualitative study, we investigated the perceptions of six Lake Victoria island communities of Koome, Uganda, about interventions to control Schistosoma mansoni infection and their willingness to participate in Schistosoma vaccine trials. Thirty-two in-depth interviews, 12 key informant interviews and 10 focus group discussions were conducted. Data were analysed using a thematic content approach.FindingsIntestinal schistosomiasis was not regarded as a serious health problem because a mass treatment programme is in place. However, the communities lack safe water sources and latrines. Mass treatment with praziquantel, safe water supplies and use of toilets were deemed the most acceptable interventions by the participants. The communities are willing to participate in Schistosoma vaccine trials.Conclusion/SignificanceKnowledge of a community’s perception about interventions to control schistosomiasis can be valuable to policy makers and programme implementers intending to set up interventions co-managed by the community members. In this study, the views of the Lake Victoria island communities of Koome are presented. This study also provides data to guide further work on alternative interventions such as Schistosoma vaccine trials in these communities.

show abstract

Section: Introductionmentioning

confidence: 99%

Perceptions about interventions to control schistosomiasis among the Lake Victoria island communities of Koome, Uganda

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Till date, praziquantel (PZQ) is the only drug that has been used to treat Schistosomiasis since 1970, but it does not prevent re-infection. So, repetition of the treatment with PZQ is required at frequent intervals (15)(16)(17)(18)(19). Additionally, poor activity of praziquantel against immature schistosome, its limited use for patients developed hepatosplenic lesion, and the potential of drug resistance development prohibit influential control depending on chemotherapy alone and necessitate develop and use of vaccines as a key and complementary component beside other integrated approach for the disease control and elimination (4,9,15,(19)(20)(21)(22)(23)(24).…”

Section: Introductionmentioning

confidence: 99%

Translationally Controlled Tumor ProteinTCTPas Peptide Vaccine againstSchistosoma japonicum: an Immunoinformatics Approach

Abdalrahman¹,

Ahmed²,

Elnaeem³

et al. 2018

Preprint

View full text Add to dashboard Cite

Schistosoma japonicum is the most pathogenic causative form of schistosomiasis that causes a major health problem in its endemic countries. Until now, praziquantel is the only drug used to treat Schistosomiasis, but it does not prevent re-infection. So, repetition of the treatment is needed. Moreover, there is no effective vaccine against S. japonicum. Therefore, an urgent need for the development of vaccines is mandatory. This study aimed to analyze an immunogenic protein, Transitionally Controlled Tumor Protein (TCTP) using an immunoinformatics approach to design a universal peptide vaccine against Schistosoma japonicum. A set of 22 of TCTP sequences were retrieved from NCBI database. Conservancy of these sequences was tested and then conserved B cell and T cell epitopes were predicted using different tools available in IEBD. Epitopes having high scores in both B and T cell predicting tools were proposed. An epitope 129 YEHYI 133 was predicted as a most promising epitope with good prediction scores in surface accessibility and antigenicity. Besides that, epitopes 129 YEHYIGESM 137 and 92 YLKAIKERL 100 were predicted as the most promising epitopes concerning their binding to MHC I and MHC II allele respectively. The study revealed that our predicted epitopes could be used to develop an efficacious vaccine against Schistosoma japonicum in the future especially epitope YEHYIGESM as it is shared between MHC I and II alleles and overlapped with the most promising B cell epitope. Both in vitro and in vivo studies is recommended to confirm the efficacy of YEHYIGESM as a peptide vaccine.

show abstract

“…Each year there are hundreds of millions of people infected with disease causing parasites, particularly in tropical and subtropical regions of the world, which results in an estimated 1 million deaths [1]. Unfortunately, prevention and control of tropical parasitic diseases is challenging, compounded by a lack of vaccines, issues of parasite drug resistance and vector insecticide resistances [2][3][4][5]. This alarming situation is driving increased efforts in the discovery and development of new therapeutic agents, in particular the identification of new drug leads with novel mechanisms of actions (MOA) and subsequent progression to clinical use in order to limit potential issues of cross-resistance.…”

Section: Introductionmentioning

confidence: 99%

Defining the targets of antiparasitic compounds

Skinner‐Adams

Sumanadasa

Fisher

et al. 2016

Drug Discovery Today

View full text Add to dashboard Cite

The treatment of major human parasitic infections is dependent on drugs that are plagued by issues of drug resistance. New chemotherapeutics with novel mechanisms of action (MOA) are desperately needed to combat multi-drug-resistant parasites. Although widespread screening strategies are identifying potential new hits for development against most major human parasitic diseases, in many cases such efforts are hindered by limited MOA data. Although MOA data are not essential for drug development, they can facilitate compound triage and provide a mechanism to combat drug resistance. Here we describe and discuss methods currently used to identify the targets of antiparasitic compounds, which could circumvent this bottleneck and facilitate the development of new antiparasitic drugs.

show abstract

Still hope for schistosomiasis vaccine

Cited by 21 publications

References 42 publications

Perceptions about interventions to control schistosomiasis among the Lake Victoria island communities of Koome, Uganda

Perceptions about interventions to control schistosomiasis among the Lake Victoria island communities of Koome, Uganda

Translationally Controlled Tumor ProteinTCTPas Peptide Vaccine againstSchistosoma japonicum: an Immunoinformatics Approach

Defining the targets of antiparasitic compounds

Contact Info

Product

Resources

About